Tesamorelin for Weight Loss? Read Its Own Label

Tesamorelin is a real, FDA-approved drug — sold as EGRIFTA, made by Theratechnologies, with a current label you can read today. Its approval covers exactly one job: cutting the visceral fat that builds up in people living with HIV who have developed lipodystrophy. And its label carries a limitation stated in five words: “Not indicated for weight loss management.”^[1]

It is nonetheless marketed for weight loss, frequently alongside GLP-1s, by sellers who lean on the fact that it is approved. That is the trick worth understanding: approved and approved for this are different claims, and the gap between them is where the marketing lives.

What the label actually says

Section 1 of the prescribing information describes tesamorelin as a growth hormone-releasing factor analog, and ties its approval to one use: shrinking the surplus fat carried around the abdomen by adults with HIV who have lipodystrophy. Directly beneath that, the label sets out two limitations on what it may be said to do.

“Long-term cardiovascular safety of EGRIFTA WR has not been established.”

“Not indicated for weight loss management.”^[1]

— FDA label, EGRIFTA WR (tesamorelin) — Limitations of Use

HIV-associated lipodystrophy is a specific condition: a redistribution of body fat seen in some people on long-term antiretroviral therapy, in which visceral fat accumulates around the abdominal organs. Tesamorelin was developed for that, tested in that population, and approved for that. It is a growth hormone-releasing factor analog — it nudges the pituitary into putting out more of the growth hormone you already make — which is an entirely different mechanism from a GLP-1.

This is not the BPC-157 situation

Worth being precise, because the peptide market gets discussed as though it were one undifferentiated thing. There are two current FDA labels for tesamorelin, EGRIFTA WR and EGRIFTA SV. It has a manufacturer, an approval, published trials and a prescribing information document. BPC-157 has none of those.

So the objection here is narrower and sharper. Nobody has to argue that tesamorelin is unstudied or unreal. The argument is only that it was studied for a different problem in a different population, and that the label says so on its face.

Off-label is legal — and this is not quite that

A clinician may lawfully prescribe an approved drug outside its labeled indication. Off-label prescribing is legal, common and often good medicine — Ozempic for weight loss is the obvious example in this market.

⚠ What is not the same thing is a seller marketing a drug for an unapproved use. The prescriber's judgment is protected; promotional claims are regulated. When a peptide site advertises tesamorelin for fat loss in the general population, it is making the claim the label specifically excludes, and it is making it to you rather than to a clinician exercising judgment about your case.

• Ask what indication it is being prescribed for. If you do not have HIV-associated lipodystrophy, ask directly what the clinical reasoning is.
• Ask where it is coming from. Approved EGRIFTA is dispensed by a pharmacy against a prescription. A vial from a peptide shop labeled “tesamorelin” is not that product, whatever the name on it.
• Ask about cardiovascular monitoring, given the label's own limitation on long-term cardiovascular safety.
• Ask what evidence supports the use you are being sold. Trials in HIV-associated lipodystrophy are evidence about HIV-associated lipodystrophy.

How it compares to what is actually approved for weight

If the goal is weight loss, the drugs approved for it have been tested for it at scale. Semaglutide reported 14.9% at 68 weeks in a trial of 1,961 people; tirzepatide 20.9% at 72 weeks in 2,539.^[2] Those trials measured weight in people seeking weight loss, which is the question being asked.

Tesamorelin's trials measured visceral fat in people with HIV-associated lipodystrophy. That is a real and useful finding for those patients, and it is not an answer to a different question. Our register covers the sellers of the drugs that were approved for this, and what they cost.

Common questions